<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bounaadja L</submitter><funding>Université de Haute Alsace</funding><funding>French Ministry of Research</funding><funding>CNRS</funding><funding>Agence Nationale de la Recherche</funding><funding>Muséum National d&amp;apos;Histoire Naturelle</funding><pagination>382</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5609037</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Plasmodium falciparum M1 family aminopeptidase is currently considered as a promising target for anti-malarial chemotherapy. Several series of inhibitors developed by various research groups display IC50/Ki values down to nM range on native PfA-M1 or recombinant forms and block the parasite development in culture at µM to sub-µM concentrations. A handful of these inhibitors has been tested on murine models of malaria and has shown anti plasmodial in vivo activity. However, most of these inhibitors do also target the other neutral malarial aminopeptidase, PfA-M17, often with lower Ki values, which questions the relative involvement and importance of each enzyme in the parasite biology.&lt;h4>Results&lt;/h4>An amino-benzosuberone derivative from a previously published collection</pubmed_abstract><journal>Malaria journal</journal><pubmed_title>Selective inhibition of PfA-M1, over PfA-M17, by an amino-benzosuberone derivative blocks malaria parasites development in vitro and in vivo.</pubmed_title><pmcid>PMC5609037</pmcid><funding_grant_id>MCAM</funding_grant_id><funding_grant_id>ANR-12-BS07-0020-02 MAMMAMIA</funding_grant_id><funding_grant_id>COB</funding_grant_id><funding_grant_id>LCM</funding_grant_id><pubmed_authors>Albrecht S</pubmed_authors><pubmed_authors>Mouray E</pubmed_authors><pubmed_authors>Tarnus C</pubmed_authors><pubmed_authors>Bounaadja L</pubmed_authors><pubmed_authors>Schmitt M</pubmed_authors><pubmed_authors>Florent I</pubmed_authors></additional><is_claimable>false</is_claimable><name>Selective inhibition of PfA-M1, over PfA-M17, by an amino-benzosuberone derivative blocks malaria parasites development in vitro and in vivo.</name><description>&lt;h4>Background&lt;/h4>Plasmodium falciparum M1 family aminopeptidase is currently considered as a promising target for anti-malarial chemotherapy. Several series of inhibitors developed by various research groups display IC50/Ki values down to nM range on native PfA-M1 or recombinant forms and block the parasite development in culture at µM to sub-µM concentrations. A handful of these inhibitors has been tested on murine models of malaria and has shown anti plasmodial in vivo activity. However, most of these inhibitors do also target the other neutral malarial aminopeptidase, PfA-M17, often with lower Ki values, which questions the relative involvement and importance of each enzyme in the parasite biology.&lt;h4>Results&lt;/h4>An amino-benzosuberone derivative from a previously published collection</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Sep</publication><modification>2026-06-17T06:54:13.054Z</modification><creation>2019-03-27T02:57:06Z</creation></dates><accession>S-EPMC5609037</accession><cross_references><pubmed>28934959</pubmed><doi>10.1186/s12936-017-2032-4</doi></cross_references></HashMap>